Shoulder Innovations Submits IPO Filing to Raise $100 Million on Nasdaq

Recently, Cook Medical officially announced the establishment of the Interventional Magnetic Resonance (iMRI) Division. The new division will focus on the research and development, production, and clinical application promotion of magnetic resonance imaging systems. Cook Medical stated that its first-phase investment reached 230 million US dollars, with plans to launch three MRI devices covering different clinical scenarios within the next five years. These include a 1.5T whole-body MRI system using superconducting magnet technology, a high-field open MRI optimized for neurology, and a portable low-field MRI solution. Data shows that Cook Medical is a global large-scale minimally invasive medical device company dedicated to the research and development, production, and sales of minimally invasive medical devices. Its products span nearly 60 clinical disciplines, covering vascular intervention, endoscopy, surgery, urology, intensive care, and more. The establishment of this new division marks an important step in transforming the way complex surgeries are performed and addressing unmet clinical needs.

Recently, Jiuzhou Tong's equipment subsidiary, Jiuzhou Tong Medical Equipment Group Co., Ltd., joined hands with Shanghai Zhihan Medical Technology Co., Ltd. to jointly establish Jiuzhou Tong Xinkang (Shanghai) Medical Equipment Co., Ltd. This is the 15th medical company that Jiuzhou Tong Medical Equipment has invested in since 2025. The registered capital of this new company reaches 20 million yuan, with Jiuzhou Tong Equipment holding a 51% stake, taking the leading position, while Shanghai Zhihan Medical holds 49% of the shares. Its business scope is extensive, covering both licensed projects such as the operation of Class III medical devices and pharmaceutical wholesale, as well as general projects like sales of Class I and Class II medical devices, import and export of goods, and technology import and export, demonstrating its ambition for diversified development in the medical device field. Currently, Jiuzhou Tong Medical is focusing on six core areas: major surgery, interventional consumables, orthopedic consumables, IVD, nursing consumables, and medical equipment. It has established close cooperative relationships with more than 60% of the world's top 100 multinational enterprises and 80% of China’s leading industrial enterprises, including industry giants such as Philips, Neusoft, Mindray, Roche, and Alcon.

Recently, Olympus announced that it hasRevival Healthcare Capital reached a cooperation agreement to jointly establish a new company, Swan EndoSurgical, which focuses on the research and development of endoluminal surgical robots. Swan EndoSurgical is committed to developing revolutionary soft surgical robots with the aim of reshaping the future diagnosis and treatment model for gastrointestinal (GI) diseases. Surgical robots have already made significant achievements in general surgery and orthopedics, especially in the field of general surgery. However, in the field of digestive endoscopy, there hasn’t been a surgical robot as groundbreaking as the da Vinci system. Currently, companies that are advancing relatively quickly in this market include EndoQuest Robotics, Atlas Endoscopy, EndoRobotics, and Qiaojie Li, among others. Most of these companies’ products are still in clinical trials and have not yet received regulatory approval for market launch. Among them, EndoQuest Robotics is considered a promising contender, potentially becoming the first to gain FDA approval for market entry. As a leader in the field of digestive endoscopy, Olympus cannot afford to miss out on the opportunities of this rapidly evolving era after having missed the chance in disposable endoscopes; it must not let the next era’s opportunities slip away.

Recently, MicroPort® Robot, in collaboration with top-tier institutions in China such as the Chinese People's Liberation Army General Hospital and Tsinghua University, has made significant progress in the development of autonomous suturing technology for surgical robots: the completion of a prototype for autonomous suturing based on the MicroPort® Endoscopic Surgical Robot Platform, achieving experimental validation of bilateral-arm autonomous suturing on ex vivo kidneys! This breakthrough signifies that China now possesses independent innovation capabilities in the critical AI + robotics sector, leading Chinese surgical robot technology into a new phase of "artificial intelligence" development.

Recently, the Grand Opening Ceremony of Mindray's Wuhan R&D Base was Held. Chairman of Mindray Medical, Li Xiting, President Wu Hao, Senior Vice President Li Xinsheng, and other group leaders attended the event, with all Wuhan employees gathering together. As the second headquarters of the group, the Wuhan base has a total investment of 4.5 billion yuan and a total construction area of approximately 620,000 square meters. The business focus is on three major sectors: minimally invasive surgery, orthopedics, and cardiovascular-related fields, covering the entire value chain including R&D, manufacturing, and training. The Wuhan R&D Base is one of the group’s largest R&D centers. To date, it has built about 13,000 square meters of professional experimental space, over 90 laboratories, and is equipped with distinctive modules such as a global customer training and experience center and an engineering technology transformation center, comprehensively empowering the leapfrog development of innovative businesses at the Wuhan base.

Ledman Announces Plan to Acquire Up to 70% of Beijing Simcere Xiangrui Biological Products Co., Ltd. (referred to as "Simcere Xiangrui") through Cash Payment from Certain Shareholders. Upon completion of this transaction, the company will gain control of Simcere Xiangrui, which will become a controlling subsidiary. This transaction is expected to constitute a major asset restructuring. Simcere Xiangrui is mainly engaged in the production of in vitro diagnostic reagents and human vaccines, with main products including Purified Protein Derivative of Tuberculin, Purified Protein Derivative of BCG, and Mycobacterium Tuberculosis-Specific Cellular Immune Response Detection Kit, primarily applied in the fields of tuberculosis screening, diagnosis, treatment, and innovative vaccines.

Meikang Biotech recently announced that the company and its holding subsidiary, Jiangxi Meikang, have recently obtained several "People's Republic of China Medical Device Registration Certificates (In Vitro Diagnostic Reagents)" issued by the Zhejiang Provincial Drug Administration and the Jiangxi Provincial Drug Administration. These registration certificates involve products including theophylline quality control materials, phenytoin quality control materials, angiotensin II and I test kits, interleukin-1β, 2 and 2 receptor test kits, etc. The acquisition of these registration certificates will enrich the company’s product lines in the in vitro diagnostic chemiluminescence and mass spectrometry segments, which is beneficial for enhancing the company’s core competitiveness and market expansion capabilities.

Recently, the Shanghai Municipal Government held an executive meeting, requiring the implementation of the "AI + Manufacturing" initiative according to the Municipal Party Committee’s deployment, accelerating the intelligent development of the manufacturing industry; optimizing and enhancing the logistics clearance efficiency at Shanghai's aviation ports; and promoting the full-chain development of the high-end medical device industry. The meeting generally approved the "Shanghai Implementation Plan for Accelerating the Development of 'AI + Manufacturing'" and emphasized that it is necessary to seize the strategic opportunity of artificial intelligence empowering the manufacturing industry, using AI to drive the high-end, intelligent, green, and integrated upgrading of manufacturing, helping "Made in Shanghai" advance towards "Smart Made in Shanghai." The meeting also generally approved the "Shanghai Action Plan for Promoting Full-Chain Development of the High-End Medical Device Industry" and pointed out that the speed of iteration and upgrading of high-end medical devices is increasingly accelerating. It is essential to leverage the R&D advantages as an innovation source, focus on key product directions, concentrate efforts on overcoming challenges, and strive for landmark achievements. Continuous promotion of the entire chain acceleration of "R&D + Clinical + Manufacturing + Application" is required, further speeding up the review and approval process, and supporting innovative medical device products entering hospitals, stores, online platforms, and communities.

Recently, it was learned from the Henan Provincial Drug Administration that the "Implementation Opinions on Further Deepening the Reform and Innovation of Drug Regulation to Serve and Promote the High-Quality Development of the Pharmaceutical Industry," issued by the bureau, proposes 24 important reform measures in four aspects. These measures further deepen the reform and innovation of drug regulation, providing strong support for enhancing the compliance level of the pharmaceutical industry and stimulating the vitality of industrial innovation and development. The Implementation Opinions propose a series of new measures, such as striving for national pilot projects on drug regulatory reforms, improving the quality and efficiency of clinical trials for innovative drugs and devices, promoting the steady development of generic drugs, relying on technical support resources to serve industrial development, and collaboratively building platforms for the research and transformation of innovative drugs and devices, all aimed at fully serving the research, development, and market entry of innovative drugs and devices, and fostering the development of new productive forces in the pharmaceutical field. The main contents include actively striving for the National Medical Products Administration (NMPA) to optimize the reform pilot of the supplementary application review and approval process for drugs, optimizing the pilot program for the review and approval of clinical trials for innovative drugs, following up to secure pilot programs for segmented production of biological products, promoting the early implementation of major national drug review and approval reform deployments in Henan, and assisting in empowering the research, development, and market entry of innovative products.

Recently, the Anhui Provincial Drug Administration released the "Announcement on the Activation of the First Batch of Electronic Licenses," clarifying that starting from August 1, 2025, the first batch of eight administrative approval-related electronic licenses for enterprises will be officially activated. This move aims to "reduce the burden and accelerate processes" for enterprises through digital reform, further enhancing the efficiency of government services in the pharmaceutical regulatory field. The announcement stipulates that the licenses included in electronic management involve eight administrative approval items such as drug production, drug distribution, medical device production, cosmetic production, hospital preparation, and the production, operation, and use of radioactive drugs. The electronic licenses include the original,副本,附页, and pages recording changes, covering all approval information after August 1, 2025, achieving full-process digital recording and management of approval matters.

Learned from the Henan Provincial Drug Administration that the "Implementation Opinions on Further Deepening the Reform and Innovation of Drug Regulation to Serve and Promote the High-Quality Development of the Pharmaceutical Industry," issued by the bureau, proposes 24 significant reform measures in four aspects. These measures further deepen the reform and innovation of drug regulation, providing strong support for enhancing the compliance level of the pharmaceutical industry and stimulating the vitality of industrial innovation and development. The "Implementation Opinions" propose a series of new initiatives, including striving for national pilot programs for drug regulatory reform, improving the quality and efficiency of clinical trials for innovative drugs and devices, promoting the steady development of generic drugs, relying on technical support resources to serve industrial development, and collaboratively building platforms for the research and transformation of innovative drugs and devices. These initiatives aim to fully serve the research, development, and market entry of innovative drugs and devices and foster the development of new productivity in the pharmaceutical field. The main contents include actively striving for the National Medical Products Administration (NMPA) to optimize the reform pilot of the supplementary application review and approval process for drugs, optimizing the pilot program for the review and approval of clinical trials for innovative drugs, following up to secure segmented production pilots for biologics, promoting the early implementation of major deployments of national drug review and approval reforms in Henan, and assisting in empowering the research and market entry of innovative products.

Mexico Issues New Guidelines on July 18 to Accelerate Medical Device Registration by Recognizing International Certifications